# LEAD Grants - Europe

**Qualifying Criteria**
In order to qualify, a local organisation must be:

- a recognised patient advocacy organisation representing individuals advocating for access to plasma/recombinant therapies and other innovative therapies to treat bleeding disorders, immune disorders, Alpha 1 deficiency, Hereditary Angioedema, or Sickle Cell disease
- a non-profit organisation
- an organisation currently addressing a specific advocacy issue or intending to address such an issue

If you would like to learn more, please contact EUadvocacy@cslbehring.com..

Submit completed applications electronically by the deadline of **13 February 2022** to: EUadvocacy@cslbehring.com.

In order to be considered for a European LEAD Grant award, your application must be received by the deadline noted above. Grant recipients will be announced in March 2022.

Please answer the following questions and provide as much detail as possible describing the opportunity for European LEAD Grant funding. Please feel free to submit any supporting documentation that would be helpful to explain the proposal:

1. What advocacy issue would the European LEAD Grant address?
2. What is the desired impact resulting from addressing this issue?
3. Please describe the time frame for implementing the project, including key milestones.
4. What is your overall projected budget for this advocacy initiative?

All grantees will be required to submit a progress report six months from receipt of funding on activities and achievements to-date.

Any additional relevant information or support material may be included with the application.

**Examples**
Examples of advocacy issues for a LEAD Grant:

- Creative advocacy endeavors designed to address a local public policy issue or to positively impact users of plasma-derived, recombinant or other innovative therapies

- The pursuit of standard-of-care or quality-of-care legislation or regulations for plasma-derived therapies, their recombinant alternatives or other innovative therapies
- The pursuit of legislation or regulations that will increase early diagnosis and access for patients to obtain their plasma-derived, recombinant or other innovative therapy
- The creation of a grassroots program to influence local legislation